Search Results
Your search for all items matches 33999 pages
Showing 601 - 650Having Acute Lymphoblastic Leukemia Took Away My Fear of Death
On May 30, 2017, 9 days before I turned 19 and soon after I had completed my sophomore year at college, I was diagnosed with aggressive acute lymphoblastic leukemia. But getting to the diagnosis was a tortuous process. I had been feeling fatigued and losing weight for several weeks prior to the...
Chronic Graft-vs-Host Disease: Clinical Trial Updates
Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of...
Breaking the Silence: Addressing Sexual and Reproductive Health in Cancer Care
For patients with cancer and cancer survivors, sexual dysfunction and reproductive health concerns are often the elephant in the exam room—a significant quality-of-life issue that both patients and clinicians struggle to discuss openly and effectively. At the recent NCCN Policy Summit on Sexual and ...
Novel Antibody-Drug Conjugate Extends Survival vs Chemotherapy in Triple-Negative Breast Cancer
The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, according to the results of OptiTROP-Breast01, a phase III study presented at the 2024 ASCO Annual...
AMA House of Delegates Adopts Record Six ASCO-Led Resolutions
Delegates from the Association for Clinical Oncology (ASCO) participated in the 2024 Annual Meeting of the American Medical Association (AMA) House of Delegates (HOD) on June 7 to 12 in Chicago. ASCO created and was the primary sponsor of six resolutions that the AMA HOD adopted as policy, an...
ASCO Issues New Guidance on Vaccinations for Adults With Cancer
A new ASCO Clinical Practice Guideline recommends several vaccinations (eg, seasonal, herpes zoster, human papillomavirus [HPV], and others) for adults with solid or hematologic malignancies because of heightened infection risks from vaccine-preventable illnesses.1 The guideline covers the...
Factors Impacting Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer
In a Danish study reported in the Journal of Clinical Oncology by Schmidt et al, it was found that living alone and being unemployed were associated with reduced adherence to adjuvant endocrine therapy among premenopausal women with breast cancer. Study Details The study involved data from a...
Relapsed or Refractory Neuroblastoma: Addition of Dasatinib/Rapamycin to Irinotecan/Temozolomide
In a German-Austrian phase II trial (RIST-rNB-2011) reported in The Lancet Oncology, Corbacioglu et al found that the combination of dasatinib plus rapamycin and irinotecan plus temozolomide (RIST) improved progression-free survival vs irinotecan/temozolomide alone in patients with high-risk...
Stiripentol Could Prolong Efficacy of Chemotherapy in Patients With Gastric Cancer
Targeting lactate with the epilepsy drug stiripentol may reverse chemotherapy resistance in patients with gastric cancer, according to a recent study published by Chen et al in Nature. Background Chemotherapy attacks cancer cells by damaging their DNA. The cancer cells then try to rapidly repair...
Infection Risk in Patients With Mantle Cell Lymphoma
Patients with mantle cell lymphoma may be susceptible to certain diseases and may benefit from evaluation for the risk of infection, according to a recent study published by Abalo in HemaSphere. Background “Patients [with mantle cell lymphoma] live with an increased risk of infections for many...
Nasopharyngeal Carcinoma: Adding Sintilimab to Standard Chemoradiotherapy for Locoregionally Advanced Disease
Based on the results of the Chinese multicenter phase III CONTINUUM trial, which were reported in The Lancet by Liu et al, the addition of the PD-1 inhibitor sintilimab to standard chemoradiotherapy seemed to improve event-free survival—albeit with more frequent but manageable adverse events—in...
Advanced/Metastatic Genitourinary Tumors: Cabozantinib/Nivolumab With or Without Ipilimumab
As reported in the Journal of Clinical Oncology by Andrea B. Apolo, MD, and colleagues, findings in expansion cohorts of a phase I study showed the activity of cabozantinib/nivolumab alone or with the addition of ipilimumab in patients with advanced/metastatic genitourinary (GU) tumors. Study...
Germline Risk of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Results from the ECOG-ACRIN EAZ171 trial—reported in the Journal of Clinical Oncology by Schneider et al—showed that germline predictors of taxane-induced peripheral neuropathy were not associated with an increased risk of taxane-induced peripheral neuropathy in Black women with early-stage breast...
Tumor Surveillance in Pediatric Patients With Cancer Predisposition Syndromes
In a single-center study reported in JAMA Oncology, Blake et al found that surveillance among pediatric patients with cancer predisposition syndromes can result in the early detection of new tumors. As stated by the investigators, “Pediatric oncology patients are increasingly recognized as having...
Survivorship Standards at Commission on Cancer–Accredited Cancer Care Facilities
Only a minority of adult cancer survivors may have access to specialized survivorship services such as those addressing fertility and sexual health issues, and having survivorship standards in place may help cancer centers better provide services that meet the distinct needs of these patients,...
Can Adhering to a Mediterranean Diet Reduce Mortality in Cancer Survivors?
Cancer survivors who adhere to a Mediterranean diet may survive longer and have a reduced risk of cardiovascular-related mortality compared with those who had lower adherence to the diet, according to a recent study published by Bonaccio et al in JACC: CardioOncology. Background The Mediterranean...
Advanced Melanoma: Efficacy of Monoclonal Antibody Doublet
In a phase I trial reported in the Journal of Clinical Oncology, Omid Hamid, MD, and colleagues found that the combination of the human lymphocyte activation gene-3 (LAG-3)-targeting monoclonal antibody fianlimab plus the PD-1–targeting monoclonal antibody cemiplimab-rwlc was active in patients...
Endometrial Thickness in Triage for Endometrial Cancer Among Black Women
In a study reported in JAMA Oncology, Kemi Doll, MD, MSCR, and colleagues found that ultrasonography-measured endometrial thickness was not reliable in triage for diagnosing endometrial cancer among Black women. Study Details The retrospective U.S. multicenter study focused on data from 1,494 women ...
Novel Algorithm May Help to Identify Aggressive Basal Cell Carcinoma
A novel algorithm may help physicians to identify which patients have a highly aggressive subtype of facial basal cell carcinoma, according to a recent study published by Ceder et al in Dermatology Practical & Conceptual. Background Basal cell carcinoma—the most common type of skin...
Exploring Health-Care Provider Attitudes Toward HPV Self-Collection Testing
Investigators found that more than 50% of health-care providers surveyed might offer human papillomavirus (HPV) self-collection testing to their patients if the U.S. Food and Drug Administration (FDA) approved the procedure, according to a recent study published by Fontenot et al in Women’s Health...
American Indian and Alaskan Native Women May Be Less Likely to Undergo Breast Reconstruction
Investigators have identified disparities in the rates of breast reconstruction following mastectomy among American Indian and Alaskan Native women compared with non-Hispanic White women, according to a recent study published by White et al in Plastic and Reconstructive Surgery. Background Breast...
Exercise May Prevent Nerve Damage During Chemotherapy
Physical exercise may help prevent nerve damage in patients receiving chemotherapy, according to a recent study published by Streckmann et al in JAMA Internal Medicine. Background Cancer therapies have improved in recent years. Physicians are no longer concerned just about survival; patients’...
Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients
As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma....
Risk of Adverse Obstetric Outcomes in Adolescent and Young Adult Cancer Survivors
In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications. “Therefore, any pregnancy [in these...
MAST Trial: Metformin Does Not Slow Disease Progression of Low-Risk Prostate Cancer
The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting.1 In addition, the use of metformin was...
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio...
Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma
Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...
Previously Untreated EGFR-Mutated Advanced NSCLC: Amivantamab/Lazertinib vs Osimertinib
As reported in The New England Journal of Medicine by Byoung Chul Cho, MD, PhD, and colleagues, the phase III MARIPOSA trial has shown improved progression-free survival with amivantamab-vmjw plus lazertinib vs osimertinib in previously untreated patients with EGFR-mutated advanced non–small cell...
Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody
As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....
PSA May Be Insufficient to Detect Early Prostate Cancer in Transgender Women
Transgender women receiving hormone therapy may skew artificially low on prostate cancer screening tests, thereby providing false reassurance and potentially delaying diagnosis and treatment, according to a recent study published by Nik-Ahd et al in JAMA. The findings indicated that transgender...
Impact of Cisplatin-Based Chemotherapy on Hearing in Cancer Survivors
Researchers have uncovered the long-term effects of cisplatin-based chemotherapy on the hearing of cancer survivors, according to a recent study published by Sanchez et al in JAMA Oncology. Background Cisplatin is commonly used in chemotherapy to treat a variety of cancer types, including...
Perioperative Nivolumab in Renal Cell Carcinoma
As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma. Study ...
Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia
Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity. Background Chronic insomnia—one of the most prominent symptoms...
New Study Demonstrates Similar Outcomes Between Patients With Protocol Exceptions to Participate in Targeted Therapy Trial and Eligible Participants
Patients with treatment-refractory tumors who received eligibility and testing waivers to participate in a large basket/umbrella oncology trial demonstrated similar rates of clinical benefit and adverse events compared with patients who participated in the trial without waivers, according to recent ...
In Gastroesophageal Cancer, ‘Switch’ Maintenance Improves Outcomes Over Chemotherapy Continuation
In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in the phase III ARMANI trial significantly improved both progression-free and overall survival,...
ASCO: SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery
The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...
ASCO, Friends of Cancer Research Applaud FDA Draft Guidance
The Association for Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) are applauding efforts by the U.S. Food and Drug Administration (FDA) to broaden eligibility criteria for cancer clinical trials in order to include more diverse patient populations. In joint comments submitted on ...
ASCO to Present Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award
ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. This year’s meeting will be held in San Francisco and online on...
Primary Breast Cancer: Pretreatment Exercise Level and Distant Recurrence–Free Interval
In a French study (CANTO) reported in the Journal of Clinical Oncology, Soldato et al found that increasing pretreatment exercise levels was associated with a longer distant recurrence–free interval up to a threshold exercise level in patients with primary breast cancer. The benefit of exercise...
Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial
As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, long-term follow-up of the phase III CASSIOPEIA trial has shown improved progression-free survival with daratumumab maintenance vs observation both among newly diagnosed patients with transplant-eligible multiple myeloma who ...
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...
Strategies for Reducing the Risk of Cancers in Patients With Alcohol Dependence
Investigators have uncovered the potential benefit of undergoing alcohol rehabilitation and maintaining abstinence in patients with alcohol dependence at risk of developing alcohol-associated cancers, according to a recent study published by Schwarzinger et al in The Lancet Public Health. The...
Novel Spatial Gene-Signature Approach May Help to Predict Immunotherapy Outcomes in Patients With Melanoma
Researchers have demonstrated that spatial gene signatures may enhance the prediction of immunotherapy outcomes in patients with melanoma, according to a recent study published by Aung et al in Clinical Cancer Research. The current gene signatures used to predict immunotherapy outcomes may lack...
Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options
Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may...
Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; ...
Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP
As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...
Adding COX-2 Inhibition to Chemotherapy in PIK3CA-Activated Stage III Colon Cancer
In an analysis from the CALGB/SWOG 80702 (Alliance) trial published by Nowak et al in the Journal of Clinical Oncology, researchers found that the addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy was associated with improved disease-free survival and...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma
On June 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy. EPCORE ...
Can Chemotherapy Impact the Gut Microbiome in Patients With Breast Cancer?
Researchers have uncovered the impact of chemotherapy on the gut microbiome in patients with breast cancer, according to a recent study published by Otto-Dobos et al in Brain, Behavior, and Immunity. Background Chemotherapy is known to cause behavioral side effects, including cognitive decline....
Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence
Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology. Background Approximately 3% to 5% of all cancer diagnoses ...
